Celgene Corporation announced on July 19 that the U.S. Food and Drug Administration (FDA) has approved Otezla® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behcet’s disease. Otezla, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only…...
The VF Welcomes Jocelyn Ashford to the Board of Directors
Jocelyn Ashford wanted to serve on the VF’s Board of Directors because she has always appreciated the thoughtful, collaborative, and practical approach the VF has taken in addressing the needs of the vasculitis community. She feels that the VF is open to trying new approaches, considers new angles, and makes…...
ANCA-associated Vasculitis
An August 2020 article in Nature Reviews discusses the many aspects of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)—a group of autoimmune diseases (granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis, and microscopic polyangiitis) that causes blood vessels to swell. The vessels involved in AAV are typically capillaries, arterioles and venules but small…...
ChemoCentryx Announces Publication in The New England Journal of Medicine of Results of the Pivotal Phase III ADVOCATE Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
February 17, 2021 17:00 ET | Source: ChemoCentryx, Inc. — Treatment with avacopan in the absence of daily oral prednisone led to remission at week 26 and superiority in sustaining remission at 52 weeks compared to the prednisone group — — Avacopan’s effects on kidney function, patient Quality of Life,…...
VF Awards Research Grant to Pulmonary/Critical Care Medicine Physician at OSU
Lynn A. Fussner, MD, Assistant Professor at The Ohio State University (OSU), Division of Pulmonary, Critical Care, and Sleep Medicine, has been awarded a one-year grant from the Vasculitis Foundation (VF) for her study, “Role of Monocytes and Alpha-1 Antitrypsin in ANCA-Associated Vasculitis.” Dr. Fussner’s goal is to identify better…...
